These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 32234426)

  • 21. Differential impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on axitinib brain accumulation and oral plasma pharmacokinetics.
    Poller B; Iusuf D; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
    Drug Metab Dispos; 2011 May; 39(5):729-35. PubMed ID: 21282407
    [TBL] [Abstract][Full Text] [Related]  

  • 22. P-gp/ABCB1 exerts differential impacts on brain and fetal exposure to norbuprenorphine.
    Liao MZ; Gao C; Shireman LM; Phillips B; Risler LJ; Neradugomma NK; Choudhari P; Prasad B; Shen DD; Mao Q
    Pharmacol Res; 2017 May; 119():61-71. PubMed ID: 28111265
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation.
    Lagas JS; van Waterschoot RA; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
    Mol Cancer Ther; 2010 Feb; 9(2):319-26. PubMed ID: 20103600
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics of the KRAS
    Loos NHC; Retmana IA; Rijmers J; Wang Y; Gan C; Lebre MC; Sparidans RW; Beijnen JH; Schinkel AH
    Biomed Pharmacother; 2023 Oct; 166():115304. PubMed ID: 37586117
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The ABCB1 and ABCG2 efflux transporters limit brain disposition of the SYK inhibitors entospletinib and lanraplenib.
    Loos NHC; Sparidans RW; Heydari P; Bui V; Lebre MC; Beijnen JH; Schinkel AH
    Toxicol Appl Pharmacol; 2024 Apr; 485():116911. PubMed ID: 38527694
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interplay of OATP1A/1B/2B1 uptake transporters and ABCB1 and ABCG2 efflux transporters in the handling of bilirubin and drugs.
    Li W; Sparidans RW; Wang Y; Martins MLF; de Waart DR; van Tellingen O; Song JY; Lebre MC; van Hoppe S; Wagenaar E; Beijnen JH; Schinkel AH
    Biomed Pharmacother; 2024 Jun; 175():116644. PubMed ID: 38692057
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ABCB1 attenuates brain exposure to the KRAS
    Rijmers J; Retmana IA; Bui V; Arguedas D; Lebre MC; Sparidans RW; Beijnen JH; Schinkel AH
    Biomed Pharmacother; 2024 Jun; 175():116720. PubMed ID: 38733773
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-gp/ABCB1) transport afatinib and restrict its oral availability and brain accumulation.
    van Hoppe S; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
    Pharmacol Res; 2017 Jun; 120():43-50. PubMed ID: 28288939
    [TBL] [Abstract][Full Text] [Related]  

  • 29. P-glycoprotein, CYP3A, and plasma carboxylesterase determine brain and blood disposition of the mTOR Inhibitor everolimus (Afinitor) in mice.
    Tang SC; Sparidans RW; Cheung KL; Fukami T; Durmus S; Wagenaar E; Yokoi T; van Vlijmen BJ; Beijnen JH; Schinkel AH
    Clin Cancer Res; 2014 Jun; 20(12):3133-45. PubMed ID: 24727322
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Brain Exposure to the Macrocyclic ALK Inhibitor Zotizalkib is Restricted by ABCB1, and Its Plasma Disposition is Affected by Mouse Carboxylesterase 1c.
    Rijmers J; Sparidans RW; Acda M; Loos NHC; Epeslidou E; Bui V; Lebre MC; Tibben M; Beijnen JH; Schinkel AH
    Mol Pharm; 2024 Oct; 21(10):5159-5170. PubMed ID: 39312722
    [TBL] [Abstract][Full Text] [Related]  

  • 31. P-glycoprotein (ABCB1/MDR1) limits brain accumulation and Cytochrome P450-3A (CYP3A) restricts oral availability of the novel FGFR4 inhibitor fisogatinib (BLU-554).
    Li W; Sparidans R; El-Lari M; Wang Y; Lebre MC; Beijnen JH; Schinkel AH
    Int J Pharm; 2020 Jan; 573():118842. PubMed ID: 31759109
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of the efflux transporters Abcb1 and Abcg2 in the brain distribution of olaparib in mice.
    Song YK; Kim MJ; Kim MS; Lee JH; Chung SJ; Song JS; Chae YJ; Lee KR
    Eur J Pharm Sci; 2022 Jun; 173():106177. PubMed ID: 35341895
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment.
    Lagas JS; van Waterschoot RA; van Tilburg VA; Hillebrand MJ; Lankheet N; Rosing H; Beijnen JH; Schinkel AH
    Clin Cancer Res; 2009 Apr; 15(7):2344-51. PubMed ID: 19276246
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) restrict oral availability and brain accumulation of the PARP inhibitor rucaparib (AG-014699).
    Durmus S; Sparidans RW; van Esch A; Wagenaar E; Beijnen JH; Schinkel AH
    Pharm Res; 2015 Jan; 32(1):37-46. PubMed ID: 24962512
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Brain accumulation of the EML4-ALK inhibitor ceritinib is restricted by P-glycoprotein (P-GP/ABCB1) and breast cancer resistance protein (BCRP/ABCG2).
    Kort A; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
    Pharmacol Res; 2015 Dec; 102():200-7. PubMed ID: 26361725
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ABCB1 and ABCG2 Control Brain Accumulation and Intestinal Disposition of the Novel ROS1/TRK/ALK Inhibitor Repotrectinib, While OATP1A/1B, ABCG2, and CYP3A Limit Its Oral Availability.
    Li W; Sparidans RW; Lebre MC; Beijnen JH; Schinkel AH
    Pharmaceutics; 2021 Oct; 13(11):. PubMed ID: 34834176
    [TBL] [Abstract][Full Text] [Related]  

  • 37. P-glycoprotein, CYP3A, and Plasma Carboxylesterase Determine Brain Disposition and Oral Availability of the Novel Taxane Cabazitaxel (Jevtana) in Mice.
    Tang SC; Kort A; Cheung KL; Rosing H; Fukami T; Durmus S; Wagenaar E; Hendrikx JJ; Nakajima M; van Vlijmen BJ; Beijnen JH; Schinkel AH
    Mol Pharm; 2015 Oct; 12(10):3714-23. PubMed ID: 26317243
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of ABCB1 and ABCG2 at the Mouse Blood-Brain Barrier with Marketed Drugs To Improve Brain Delivery of the Model ABCB1/ABCG2 Substrate [
    Traxl A; Mairinger S; Filip T; Sauberer M; Stanek J; Poschner S; Jäger W; Zoufal V; Novarino G; Tournier N; Bauer M; Wanek T; Langer O
    Mol Pharm; 2019 Mar; 16(3):1282-1293. PubMed ID: 30694684
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of drug efflux and uptake transporters in the plasma pharmacokinetics and tissue disposition of morphine and its main metabolites.
    F Martins ML; Heydari P; Li W; Martínez-Chávez A; El Yattouti M; Lebre MC; Beijnen JH; Schinkel AH
    Toxicol Appl Pharmacol; 2024 Sep; 490():117040. PubMed ID: 39032800
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Breast Cancer Resistance Protein and P-Glycoprotein Influence In Vivo Disposition of 11C-Erlotinib.
    Traxl A; Wanek T; Mairinger S; Stanek J; Filip T; Sauberer M; Müller M; Kuntner C; Langer O
    J Nucl Med; 2015 Dec; 56(12):1930-6. PubMed ID: 26359257
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.